n-Butyrate % Test · Stool

Your colon lining runs almost entirely on a single fuel: a four-carbon fatty acid that your gut bacteria make when they ferment the fiber you eat. When that fuel supply drops, the cells lining your colon weaken, the barrier between your gut and bloodstream gets leakier, and inflammation can quietly build.

n-Butyrate % tells you what share of the short-chain fatty acid mix in your stool is butyrate. It is one window into how well your gut microbes are doing the fermentation work that protects your colon and influences metabolism, immunity, and the gut-brain axis.

What This Number Actually Reflects

Short-chain fatty acids (SCFAs) are the small carbon molecules your gut bacteria release when they break down fiber and resistant starch in your colon. The three main ones are acetate, propionate, and butyrate. In a typical healthy colon, butyrate makes up roughly 15% of the SCFA pool, with acetate and propionate making up the rest.

Up to about 90% of the butyrate produced in your colon is absorbed and used directly by the cells lining your gut (called colonocytes). It supports those cells, helps maintain the tight seal between them, and signals to your immune system. Butyrate is mostly produced by bacterial groups including Faecalibacterium prausnitzii, Roseburia, and related species in the Firmicutes group.

Because n-Butyrate % is a percentage rather than an absolute amount, it captures the balance of fermentation in your gut. A shift in this percentage can reflect changes in which bacteria dominate, what you are eating, how long food stays in your colon, and how much butyrate your colon is using up before it leaves the body.

Conditions That Shift the Pattern

Specific gut conditions push the SCFA mix toward higher n-butyrate fractions. In laboratory studies of mixed bacterial fermentation, n-butyrate can climb above 70% of the total acid mix when the local environment is more acidic (pH below 6), when food sits longer in the colon, when there is more substrate to ferment, and when the substrate is rich in lactate. A neutral pH and higher-protein loads tend to push the mix back toward acetate and propionate, lowering the n-butyrate share.

Inflammatory Bowel Disease

Patients with inflammatory bowel disease (IBD), an umbrella term for chronic gut inflammation conditions like ulcerative colitis and Crohn's disease, consistently show altered SCFA patterns. A meta-analysis of stool SCFA studies in IBD found that levels are disturbed in active disease and during remission, with butyrate among the affected acids. Reduced butyrate production and absorption in the colon are linked to weaker barrier function and more inflammation.

Colorectal Cancer

A systematic review and meta-analysis of stool SCFA studies in colorectal cancer found that patients had lower fecal butyrate and acetate than healthy controls, suggesting impaired microbial fermentation. A separate meta-analysis concluded that lower fecal concentrations of acetic, propionic, and butyric acids were linked to higher risk and incidence of colorectal cancer. In a small study using a stool butyrate cutoff of 5.4 micrograms per milliliter (a unit for very small concentrations), butyrate showed promise as a marker tied to gut microbial diversity in colorectal cancer patients.

Metabolic and Cardiovascular Risk

The relationship here is less straightforward than it seems. In a study of 441 community-dwelling adults, higher fecal SCFA levels (including butyrate) were associated with worse metabolic health: more obesity, more hypertension, higher gut permeability, and lower microbial diversity. The likely interpretation is not that butyrate is harmful, but that more SCFA is sitting in stool because less is being absorbed into the colon wall.

This is the apparent contradiction with the IBD and colorectal cancer findings. The reconciliation: stool butyrate measurements reflect what is left over after the colon takes its share. A high stool reading can mean either lots of production with poor absorption (a sign of barrier or transport problems) or simply lots of production. Pattern, context, and trend matter more than a single number in isolation.

Other Conditions Linked to Lower Butyrate Capacity

Reduced butyrate or fewer butyrate-producing bacteria have been observed in several other settings:

• Type 2 diabetes and obesity: lower butyrate-producing bacteria are tied to insulin resistance and worse glucose control in human cohorts, with one large genetic analysis suggesting butyrate production has a causal effect on improving insulin response.
• Autism spectrum disorder: Chinese children with autism showed lower fecal butyrate and altered gut microbiota compared to controls.
• Parkinson's disease: patients had lower fecal butyrate but higher plasma butyrate, with both patterns linked to worse motor severity in a study of 181 people.
• Chronic fatigue syndrome (myalgic encephalomyelitis): in 197 patients, deficient butyrate-producing capacity in the gut microbiome was linked to bacterial network disturbances and fatigue symptoms.

Reference Ranges

n-Butyrate % is a research-grade marker. There are no consensus clinical cutpoints, no guideline body has set thresholds, and assays differ between labs. The range below comes from descriptive physiology in published literature, not a validated clinical reference population. Treat it as orientation, not a target. Your lab may report different numbers depending on its analytical method (commonly gas chromatography-mass spectrometry, or GC-MS, a lab technique for separating and identifying small molecules).

Source: descriptive ranges drawn from published reviews of colonic SCFA physiology and mixed-culture fermentation studies. Compare your results within the same lab over time, since different labs use different assays and units.

Why One Reading Is Not Enough

Stool SCFA measurements vary considerably from day to day in the same person. A study of urinary metabolites found that intra-individual variation accounted for the majority of total variance, with only about 24% of variance reflecting stable, person-specific differences. Stool collection method, time of day, sample handling, and recent diet all influence the result.

Treating a single n-Butyrate % reading as a verdict on your gut health is a mistake. The useful information is in the trend. Establish a baseline, retest in 3 to 6 months if you are making fiber, supplement, or other dietary changes, and check at least annually if you are tracking gut health proactively. A clear directional shift across several samples is more meaningful than any single value.

When Results Can Be Misleading

Several factors can distort a single n-Butyrate % reading without reflecting a real change in your gut biology:

• Sample handling: stool SCFA values are sensitive to how the sample is stored. Lyophilization (freeze-drying) gives more reproducible readings, while delays before freezing can shift the SCFA pattern.
• Time of day and stool collection method: the first full bowel movement of the day tends to produce more reproducible results, and freezing immediately after collection improves accuracy.
• Recent diet: what you ate in the previous 24 to 72 hours can shift fermentation. A randomized crossover study in active women found that switching diets meaningfully changed metabolites measured shortly after exercise. A high-fiber bread swap trial showed measurable shifts in SCFA-producing bacteria within weeks.
• Bacterial load normalization: SCFA concentration alone can mislead. Normalizing to bacterial count improves discrimination between healthy and disturbed gut microbes, especially in conditions like Clostridioides difficile infection.

What to Do With an Abnormal Result

Because n-Butyrate % is a research-grade marker without validated clinical thresholds, a single abnormal reading should not drive a major decision. Instead, treat it as a signal to investigate further. If your reading is unusually high or low, the next step is usually to retest, ideally with attention to consistent sample handling and similar diet in the days before.

If the pattern persists, the most informative next layer is a broader stool workup that includes overall SCFA concentrations, microbiome composition (especially butyrate-producing bacteria like Faecalibacterium prausnitzii and Roseburia), markers of gut barrier and inflammation (calprotectin, secretory IgA), and pancreatic elastase to rule out maldigestion. If you have ongoing gastrointestinal symptoms, a gastroenterologist is the right specialist to coordinate that workup. If the picture suggests a metabolic angle (low butyrate producers in someone with insulin resistance, for example), pairing this with markers of glucose control makes the result actionable rather than abstract.